Statins do not inhibit the FGFR signaling in chondrocytes

B Fafilek1, M Hampl2, N Ricankova3

  • 1Department of Biology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic.

Abstract

Insights

Statins do not inhibit fibroblast growth factor receptor 3 (FGFR3) signaling in chondrocytes. This suggests statin benefits for FGFR3-related chondrodysplasia may not originate within growth plate cartilage.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Genetics

Background:

  • Statins, cholesterol-lowering drugs, may counteract aberrant fibroblast growth factor receptor 3 (FGFR3) signaling.
  • FGFR3 mutations cause human dwarfing conditions, presenting a potential therapeutic target for statins.
  • The mechanism of statin action on FGFR3 signaling remains unclear.

Purpose of the Study:

  • To investigate the effect of statins on FGFR signaling in chondrocytes.
  • To determine if statins can inhibit FGFR3-mediated effects in cartilage cells.

Main Methods:

  • Primary chondrocytes, mouse embryonic tibia, and limb bud micromasses were treated with FGF2 to activate FGFR signaling.
  • The effects of four statins (atorvastatin, fluvastatin, lovastatin, pravastatin) were evaluated.
  • Assessed FGFR3 protein stability and FGFR-mediated chondrocyte growth arrest, ECM loss, senescence, and differentiation.

Main Results:

  • Statins did not alter FGFR3 protein expression levels.
  • No statin treatment affected FGFR-mediated inhibition of chondrocyte proliferation.
  • Statins did not impact FGFR-mediated hypertrophic differentiation in any model system.

Conclusions:

  • Statins do not inhibit FGFR signaling within chondrocytes.
  • The previously observed statin-mediated rescue of FGFR3-related chondrodysplasia is unlikely to be an intrinsic effect of the growth plate cartilage.
  • Further research is needed to elucidate the mechanism behind statin's therapeutic effects in chondrodysplasia models.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K